| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000018163 |
| Receipt No. | R000021041 |
| Official scientific title of the study | An MEG study regarding the neural mechanisms of assessing the future level of fatigue. |
| Date of disclosure of the study information | 2015/07/10 |
| Last modified on | 2016/07/04 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | An MEG study regarding the neural mechanisms of assessing the future level of fatigue. | |
| Title of the study (Brief title) | An MEG study regarding the neural mechanisms of assessing the future level of fatigue. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To clarify the neural mechanisms of assessing the future level of fatigue. |
| Basic objectives2 | Others |
| Basic objectives -Others | To investigate the neural mechanisms of fatigue |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The MEG data |
| Key secondary outcomes | Questionnaires |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Cognitive task 1, Cognitive task 2 | |
| Interventions/Control_2 | Cognitive task 2, Cognitive task 1 | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Healthy adult | |||
| Key exclusion criteria | Participants with past or current history of serious medical illness and/or brain organic disease, who take central nerve system acting drugs, who are contradicted for the use of MRI, and who are judged as not suitable for participation in this study. | |||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Masaaki Tanaka |
| Organization | Osaka City University Graduate School of Medicine |
| Division name | Physiology |
| Address | 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585 |
| TEL | 06-6645-3711 |
| m5914885@msic.med.osaka-cu.ac.jp | |
| Public contact | |
| Name of contact person | Akira Ishii |
| Organization | Osaka City University Graduate School of Medicine |
| Division name | Physiology |
| Address | 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585 |
| TEL | 06-6645-3711 |
| Homepage URL | |
| a.ishii@med.osaka-cu.ac.jp | |
| Sponsor | |
| Institute | Osaka City University Graduate School of Medicine |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | The Ministry of Education, Culture, Sports, Science and Technology of Japan |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 大阪市立大学医学部附属病院(大阪), Osaka City University Hospital (Osaka) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021041 |